Whether the SNY-BIVV and CELG-JUNO deals work out is a question that cannot be answered today, but the question is beside the point. Whatever happens with these two deals, 2018 is certainly going to be a big year for biotech M&A:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.